Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
NRG Oncology
University of Pavia
Instituto Oncoclinicas
Instituto Nacional de Cancer, Brazil
Mucosa Innovations, S.L.
University of California, Irvine
Chiayi Christian Hospital
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University of Pavia
German University in Cairo
University of Pennsylvania
West China Hospital
Stony Brook University
MitoImmune Therapeutics
University of Barcelona
Fundacion Clinica Valle del Lili